PeptideStack
5.2kquestions
20kanswers
220users

Does racemisation of dulaglutide at room temperature show up as a loss of content or of purity?

Asked 29 Jan 2025Modified 14 months agoViewed 22k times
27

For reference: racemisation · dulaglutide · room temperature.

I can predict the outcome but I cannot explain it, which means I will get the next case wrong.

I would like to know how confident the field actually is about this.

Can someone derive this rather than assert it?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
dulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
shareeditfollowflag
HP
askedhana_petrikova10k1429 Jan 2025

5 Answers

Sorted by votes
37

At room temperature it can show up as either, and which one depends entirely on whether the product still elutes under the main peak. Purity is a ratio of areas, so a degradant only costs purity if the method resolves it. Content is a mass against a standard, so a degradant costs content whenever the parent is consumed — resolved or not. A stereocentre inverts. Identical mass, identical formula; only a chiral method or a peptide map with a chiral digestion sees it at all. That is why the two measurements are not interchangeable and why an unchanged purity figure after an excursion to room temperature is weak evidence: the method may simply be integrating the degradant along with the parent and reporting the sum as one peak.

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

To be exact about it, hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
ZM
answeredzainab_mustafa21k278 May 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
25

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

edited 25 May 2025 by esben_lykke — added the citation requested in comments

shareimprove this answerflag
EL
answeredesben_lykke84k15827 Apr 2025
20

Start with the sequence, because which pathways are available depends on which residues are present.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Sequence determines which pathways apply, so general statements are general.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
RC
answeredRP_C18105k34830 Jan 2025
4I have kept vials both ways for a year and this matches what I saw. – second_lot 9 months ago
add a comment
17

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
HP
answeredh_pergande71k15819 May 2025
15

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
MO
answeredmarta_okonkwo190k25824 Mar 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.